



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Saturday, November 21, 2009

Accentia BioPharmaceuticals

[View the current Accentia BioPharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/bioporporate/30827-Accentia+BioPharmaceuticals.html)

(<http://www.bioportfolio.com/bioporporate/30827-Accentia+BioPharmaceuticals.html>)

Contact Details:

**324 South Hyde Park Ave., Suite 350
Tampa**

Tel: (813) 864-2554

Fax: (813) 258-6912

Email:

33606

United States of America

Our mission is to identify, develop, and market innovative biopharmaceuticals to fulfill unmet medical needs which alleviate human suffering caused by disease. Accentia BioPharmaceuticals is a vertically-integrated biopharmaceuticals company focused on the acquisition, development and commercialization of late stage specialty pharmaceuticals and biologics for targeted therapeutics. Corporate Background Accentia BioPharmaceuticals, Inc (Nasdaq:ABPI) is a vertically-integrated specialty biopharmaceutical company, formed by the Hopkins Capital Group, LLC and affiliates to acquire late-stage targeted therapeutics and to use patented delivery technologies to enhance the performance of these therapeutics. The Company consists of two wholly-owned subsidiaries, and a majority, controlling interest in a third company. Together, these assets provide for a comprehensive ability to commercialize biopharmaceuticals. Accentia partners with physicians, insurers, and pharmaceutical manufacturers to guide optimal drug development and patient care, both in the United States and in Europe. Accentia BioPharmaceuticals is focused on the commercialization of "targeted" therapeutics in patent-protected drug delivery technologies related to respiratory, oncology and critical care. Targeted therapeutics represent a rapidly growing market in pharmaceuticals, as well as in private equity spending with nearly \$700 million already invested to date in 2003. Indeed the genomic revolution now offers the key means to identify targeted therapeutics. Targeted therapeutics may be synthetic chemicals or naturally occurring products called biologics, such as nucleotides, peptides, cytokines, monoclonal antibodies, or cells which restrict their action to specific cellular targets, thereby reducing undesirable collateral damage (i.e. toxicity), while boosting efficacy. As such, their extraordinary safety profiles enhance the likelihood of accelerated access to the market and their performance profiles encourage enthusiastic adoption by specialists dealing with difficult disease states. Accentia BioPharmaceuticals has chosen to accelerate its organic growth through a combination of mergers and acquisitions of companies, product acquisitions, and in-licensing of late-stage development products. Accentia, as a later-stage company with full capabilities from development to specialized distribution and a rich pipeline of products, is well-positioned to become a market leader in the Biopharmaceutical industry.

Press Releases on Accentia BioPharmaceuticals:

[Eiger BioPharmaceuticals
Raises US\\$7.1 Million
'A' Round](#)

24th February,
2009

PALO ALTO, California, February 24 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a start-up biotechnology company developing antiviral therapies, announced that it has raised US\$7.1 million in a

[Eiger BioPharmaceuticals
Raises \\$7.1 Million
'A' Round](#)

24th February,
2009

Eiger BioPharmaceuticals,
Inc.

PALO ALTO, Calif., Feb. 24 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a start-up biotechnology company developing antiviral therapies, announced that it has raised \$7.1 million in a Series A

[Mindset
BioPharmaceuticals \(USA\)
Inc Obtains Notice of
Allowance for European
Patent Related to Use of
Insulin Sensitizers in
Senile Dementia,
Dementia and Memory
Loss](#)

24th February,
2009

NEW YORK, February 24 /PRNewswire/ -- Mindset BioPharmaceuticals (USA) Inc ("MINDSET") a company privately held by MPM Capital and other shareholders announced today that it has received a

[Food and Drug Law
Institute Sponsors Major
Conference on
Nanotechnology Law,
Regulation and Policy](#)

7th January,
2009

Food and Drug Law
Institute

Top Government Officials Will Explain Regulatory Plans for Cutting-Edge Technology at National Meeting Feb. 18-19 in Washington, DC. WASHINGTON, Jan. 7 /PRNewswire-USNewswire/ -- Nanotechnology was

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

